Document resource
For decades, tubo-ovarian cancer has been the most lethal gynaecological malignancy, with negligible improvement in the 5-year survival rates over the past decades despite advancements in treatment. This reality, described in the European Society of Gynaecological Oncology (ESGO) consensus report, underscores the urgency of effective prevention strategies.1 The growing recognition that many high-grade serous ovarian cancers originate from the fallopian tube has catalysed a paradigm shift: prevention lies in removing the fallopian tube, not the ovary.